CATALOGO DEI PRODOTTI DELLA RICERCA

SENNA, Gianenrico
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.967
EU - Europa 6.266
AS - Asia 5.178
SA - Sud America 761
Continente sconosciuto - Info sul continente non disponibili 236
AF - Africa 184
OC - Oceania 7
Totale 19.599
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.781
RU - Federazione Russa 2.976
SG - Singapore 2.225
CN - Cina 1.177
IT - Italia 1.060
GB - Regno Unito 615
BR - Brasile 578
VN - Vietnam 510
HK - Hong Kong 482
FR - Francia 335
DE - Germania 325
SE - Svezia 270
IE - Irlanda 263
BD - Bangladesh 197
KR - Corea 156
FI - Finlandia 142
IN - India 107
CA - Canada 98
JP - Giappone 69
AR - Argentina 62
MX - Messico 60
NL - Olanda 52
ZA - Sudafrica 43
ES - Italia 42
ID - Indonesia 41
TR - Turchia 41
UA - Ucraina 41
PL - Polonia 35
IQ - Iraq 32
NG - Nigeria 30
TG - Togo 27
BJ - Benin 25
CO - Colombia 25
VE - Venezuela 25
AT - Austria 23
EC - Ecuador 22
SA - Arabia Saudita 22
BE - Belgio 20
CL - Cile 20
MA - Marocco 15
PK - Pakistan 15
UZ - Uzbekistan 13
JO - Giordania 11
PY - Paraguay 11
LT - Lituania 10
AZ - Azerbaigian 9
KE - Kenya 9
PH - Filippine 9
CR - Costa Rica 8
NP - Nepal 8
AE - Emirati Arabi Uniti 7
CH - Svizzera 7
NO - Norvegia 7
PE - Perù 7
UY - Uruguay 7
AU - Australia 6
EG - Egitto 6
IL - Israele 6
MY - Malesia 6
CZ - Repubblica Ceca 5
DZ - Algeria 5
JM - Giamaica 5
KZ - Kazakistan 5
SN - Senegal 5
AL - Albania 4
BG - Bulgaria 4
LB - Libano 4
PT - Portogallo 4
RO - Romania 4
SC - Seychelles 4
TN - Tunisia 4
DO - Repubblica Dominicana 3
HU - Ungheria 3
KG - Kirghizistan 3
LV - Lettonia 3
OM - Oman 3
SK - Slovacchia (Repubblica Slovacca) 3
SY - Repubblica araba siriana 3
TH - Thailandia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
BO - Bolivia 2
DM - Dominica 2
ET - Etiopia 2
EU - Europa 2
HN - Honduras 2
HR - Croazia 2
LK - Sri Lanka 2
MD - Moldavia 2
MG - Madagascar 2
ML - Mali 2
PA - Panama 2
RS - Serbia 2
TT - Trinidad e Tobago 2
XK - ???statistics.table.value.countryCode.XK??? 2
YE - Yemen 2
AF - Afghanistan, Repubblica islamica di 1
AM - Armenia 1
AO - Angola 1
Totale 19.347
Salva come PNG Salva come JPEG
Città #
Singapore 1.156
Moscow 1.001
Ashburn 961
San Jose 833
Dallas 730
Chandler 627
Hong Kong 473
Southend 422
New York 327
Verona 316
Beijing 268
Dublin 258
The Dalles 248
Council Bluffs 195
Jacksonville 159
Ho Chi Minh City 151
Los Angeles 151
Woodbridge 145
Hanoi 111
Lawrence 109
Princeton 109
Houston 92
Wilmington 90
Munich 89
Buffalo 86
Ann Arbor 75
Sindelfingen 74
Milan 73
Tokyo 61
Helsinki 60
Jinan 60
São Paulo 60
London 57
Redondo Beach 53
Shenyang 53
Santa Clara 50
Columbus 49
Rome 49
Boardman 39
Bologna 39
Nanjing 39
Denver 38
Redmond 37
Chennai 36
Hebei 36
Guangzhou 35
Orem 34
Montreal 33
Johannesburg 32
Brooklyn 30
Warsaw 30
Abuja 29
Haiphong 29
Seattle 29
Turku 29
Amsterdam 28
Redwood City 27
Changsha 26
Lomé 26
Ningbo 26
Poplar 26
Cotonou 25
Da Nang 25
Tianjin 25
Rio de Janeiro 24
Toronto 24
Kent 23
San Francisco 23
Stockholm 23
Haikou 22
Naples 22
Nanchang 21
Norwalk 21
Dong Ket 20
Frankfurt am Main 20
Nuremberg 20
Mexico City 19
Mumbai 19
Taizhou 19
Atlanta 18
Chicago 18
Taiyuan 18
Brussels 17
Hangzhou 17
Zhengzhou 17
Boston 16
Phoenix 16
Falkenstein 15
Jakarta 15
Manchester 15
Bari 14
Padova 14
Ankara 13
Baghdad 13
Tashkent 13
Florence 12
Seoul 12
Turin 12
Vienna 12
Curitiba 11
Totale 11.317
Salva come PNG Salva come JPEG
Nome #
Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management 459
Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis 230
Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels 212
Allergen specific immunotherapy is safe and effective in patients with systemic mastocytosis and hymenopteria allergy 210
Fatal asthma; is it still an epidemic? 210
Allergic Reactions to COVID-19 Vaccines: Risk Factors, Frequency, Mechanisms and Management 203
Safety of Biologic Therapies for Severe Asthma: An Analysis of Adverse Reactions Reported in the WHO Pharmacovigilance Database 198
Study on the Immunoreactivity of Triticum monococcum (Einkorn) Wheat in Patients with Wheat-Dependent Exercise-Induced Anaphylaxis for the Production of Hypoallergenic Foods 189
La salute del respiro: epidemiologia, costi sanitari ed implicazioni sociali delle malattie respiratorie croniche in Europa e in Italia 186
Allergic rhinitis: pharmacotherapy in pregnancy and old age 186
Asthmatic patients in COVID-19 outbreak: Few cases despite many cases 183
COVID-19 Vaccination in Patients with Severe Asthma on Biologic Treatment: Safety, Tolerability, and Impact on Disease Control 181
Allergy and the bone: unexpected relationships 179
Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity 179
Asthma control in primary care: the results of an observational cross-sectional study in Italy and Spain 177
Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience 172
Adverse reaction to local anaesthetics: Is it always allergy? 172
Analysis of the positivity rate in IgE positive patients to inhalant allergens in Verona Hospital Laboratory during 2002-2003 168
A double-blind placebo-controlled study on the diagnostic accuracy of an electrodermal test in allergic subjects 165
A hierarchical cluster analysis of the psycological impact of the COVID-19 pandemic on Italian severe asthma patients 163
Onset of eosinophilic granulomatosis with polyangiitis in a patient treated with an IL-5 pathway inhibitor for severe asthma 161
Clinical response to biologicals for severe asthma: any relevance for sex in different age ranges? 160
Biologics for Eosinophilic Granulomatosis with Polyangiitis: one size does not fit all 159
Evaluation of asthma control in the pharmacy: an Italian cross-sectional study 156
Asthma under/misdiagnosis in primary care setting: an observational community-based study in Italy 156
Allergen Immunotherapy Adherence in the Real World: How Bad Is It and How Can It Be Improved? 156
Importance of Cardiopulmonary Exercise Testing amongst Subjects Recovering from COVID-19 156
Successful switching from mepolizumab to dupilumab in a patient with EGPA in remission phase and persistent nasal polyposis 156
Periostin: The bone and beyond 153
COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey 152
Allergen-specific immunotherapy and COVID-19: What happened? 151
Thunderstorm Asthma: A Critical Appraisal Based on Clinical Practice 151
Biologics and global burden of asthma: A worldwide portrait and a call for action 148
Low‑dose anti‑IL 5 treatment in idiopathic hypereosinophilic syndrome: towards a precision medicine approach for remission maintenance 148
Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy 147
Anaphylaxis and intimate behaviour 146
Residual Lung Function Impairment Is Associated with Hyperventilation in Patients Recovered from Hospitalised COVID-19: A Cross-Sectional Study 145
New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic 143
ALLERGY AND CORONAVIRUS DISEASE (COVID-19) INTERNATIONAL SURVEY: REAL-LIFE DATA FROM THE ALLERGY COMMUNITY DURING THE PANDEMIC 143
Profiling blood hypereosinophilia in patients on dupilumab treatment for respiratory conditions: a real-life snapshot 142
Idiopathic hypereosinophilic syndromes and rare dysimmune conditions associated with hyper-eosinophilia in practice: An innovative multidisciplinary approach 140
Impatto socio-sanitario e livello del controllo delle patologie respiratorie croniche ostruttive e della rinite in Italia 139
Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase 139
Hidden Comorbidities in Asthma: A Perspective for a Personalized Approach 138
Timing of response and long term efficacy of Omalizumab in non-clonal Mast Cell Activation Syndrome: A case series 138
Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response 138
The potential role of local pharmacies to assess asthma control: an Italian cross-sectional study 138
Benralizumab Efficacy in Late Non-Responders to Mepolizumab and Variables Associated with Occurrence of Switching: A Real-Word Perspective 137
Anaphylaxis and Coronavirus Disease 2019 vaccine: a danger relationship? 137
Incidence and risk factors for subcutaneous immunotherapy anaphylaxis: the optimization of safety 137
COPD prevalence in a north-eastern Italian general population 135
Relationship between hair shedding and systemic inflammation in COVID-19 pneumonia 135
Multidisciplinary management in type 2 inflammatory disease 134
Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies 133
Safety of COVID-19 Vaccines Among the Paediatric Population: Analysis of the European Surveillance Systems and Pivotal Clinical Trials 132
Balancing efficacy against safety in sublingual immunotherapy with inhalant allergens: what is the best approach? 129
Adherence to Intranasal Steroids in Chronic Rhinosinusitis with Nasal Polyposis Prior to and during Biologic Therapy: A Neglected Matter 125
Systemic Reactions After Hymenoptera Sting And Raised Serum Tryptase Strongly Suggest Clonal Mast Cells Disorders 125
What lies beyond Asthma Control Test: Suggestions for clinical practice 125
Eosinophilic Granulomatosis With Polyangiitis and Cardiac Involvement: A Case Report 125
ARIA-ITALY multidisciplinary consensus on nasal polyposis and biological treatments 124
Trends and determinants of Emergency Room admissions for asthma: A retrospective evaluation in Northeast Italy 122
Uncontrolled Asthma: Unmet Needs in the Management of Patients 122
Omalizumab management beyond clinical trials: the added value of a network model 121
Relevance of TH2 markers in the assessment and therapeutic management of severe allergic asthma: A real-life perspective 121
Scombroid syndrome: it seems to be fish allergy but... it isn't 121
Different aspects of severe asthma in real life: Role of Staphylococcus aureus enterotoxins and correlation to comorbidities and disease severity 121
Anaphylaxis due to antiallergic and antiasthmatic biologics 119
Is hymenoptera venom allergy an occupational disease? 118
Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database 117
Potential benefit of omalizumab in respiratory diseases 117
Wasp venom allergy screening with recombinant allergen testing. Diagnostic performance of rPol d 5 and rVes v 5 for differentiating sensitization to Vespula and Polistes subspecies 117
How much specific is the association between hymenoptera venom allergy and mastocytosis? 117
Choosing wisely: practical considerations on treatment efficacy and safety of asthma in the elderly 117
Safety of uSCIT-MPL-4: prevalence and risk factors of systemic reactions in real life 117
Comment on: Onset of eosinophilic granulomatosis with polyangiitis in a patient treated with an IL-5 pathway inhibitor for severe asthma: reply 117
Diagnosis, management and therapeutic options for eosinophilic esophagitis 116
SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma 116
Asthma management among different specialists: results from a national Italian survey 116
Relevance of Smoking Habit in Severe Asthma Patients: Evidence from the Severe Asthma Network in Italy (SANI) Registry 114
Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study 114
Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis 114
Profiling severe asthma: Any relevance for age? An analysis from Severe Asthma Network Italy (SANI) cohort 114
Low adherence to inhaled corticosteroids/long-acting β2-agonists and biologic treatment in severe asthmatics 113
Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI) 113
The pathogenesis, epidemiology and biomarkers of susceptibility of pulmonary fibrosis in COVID-19 survivors 112
IgE to staphylococcal enterotoxins are undetectable in sera from patients with nasal polyposis 111
Targeting eosinophils: severe asthma and beyond 111
Diagnosis and Management of Allergic Rhinitis in Asthmatic Children 111
Extracellular Vesicles in Asthma: Intercellular Cross-Talk in TH2 Inflammation 110
Sex in Respiratory and Skin Allergies 110
Remission in Type 2 Inflammatory Diseases: Current Evidence, Unmet Needs, and Suggestions for Defining Remission in Chronic Rhinosinusitis with Nasal Polyps 110
The degree of serological sensitization to cat allergen in patients with or without cat at home 109
How far from correct is the use of adrenaline auto-injectors? A survey in Italian patients 109
One year of mepolizumab. Efficacy and safety in real-life in Italy 108
Omalizumab for severe allergic asthma in clinical trials and real-life studies: what we know and what we should address 108
Sex Differences in Severe Asthma: Results From Severe Asthma Network in Italy-SANI 108
Biologic Therapy in a Patient with Asthma and Nasal Polyps 105
Component resolved diagnosis (CRD): how much is it presently used by Italian allergists? 105
Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes 105
Totale 14.300
Salva come PNG Salva come JPEG
Categoria #
all - tutte 74.219
article - articoli 72.960
book - libri 536
conference - conferenze 293
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 430
Totale 148.438
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022627 0 172 19 45 16 14 15 48 50 13 51 184
2022/20231.855 139 158 190 266 179 421 31 108 222 15 86 40
2023/20241.347 52 95 121 169 115 283 89 63 20 59 192 89
2024/20253.211 160 182 152 447 124 100 119 255 499 237 264 672
2025/202610.552 689 642 726 1.745 2.663 668 881 579 782 519 284 374
2026/2027164 122 42 0 0 0 0 0 0 0 0 0 0
Totale 19.599